The Needle-Free Injection Market represents a transformative segment within the healthcare industry, offering innovative solutions for drug delivery without the use of traditional needles. This market encompasses a diverse array of technologies and devices designed to administer medications through high-pressure jets, spring mechanisms, or air pressure, thereby eliminating the discomfort associated with needle injections. Key components include jet injectors, spring-loaded devices, and needle-free syringes, providing patients and healthcare professionals with safer and more convenient alternatives for administering medications.

Major drivers of the Needle-Free Injection Market include the growing demand for painless drug delivery methods, the rising prevalence of chronic diseases requiring frequent injections, and advancements in technology enhancing the precision and efficacy of needle-free devices. These devices are particularly beneficial for pediatric patients, individuals with needle phobia, and those requiring self-administration of medications at home.

Challenges involve ensuring regulatory compliance, addressing concerns related to infection control, and optimizing device usability and reliability. Geographically, North America and Europe lead in market share due to early adoption of innovative healthcare technologies and robust research and development initiatives. As the demand for painless drug delivery solutions continues to rise globally, the Needle-Free Injection Market remains poised for significant growth and technological advancements, offering safer and more patient-friendly alternatives to traditional needle injections.

Market Research Future (MRFR) anticipates strong growth for the needle free injection market share 2023 as it is set to touch USD 142.70 million by 2030. The market could advance at a significant rate over the evaluation period (between 2018 and 2023). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Main Drivers and Top Deterrents

The COVID-19 outbreak has overwhelmed the healthcare industry, with various firms striving to boost their R&D-based efforts to fast develop a vaccine. However, vaccine is only one aspect of the big issue, the key challenge lies in the way to administer the vaccine. The situation has thrown light on the importance of the pain saver technology or needle-free injection. The devices that were used earlier to administer various drugs have now undergone various enhancements, making them more secure, more reliable and efficient.

Needle stick injuries are the major causes of transmission of several blood-borne diseases like hepatitis C, Human Immunodeficiency Virus/HIV, Acquired Immune Deficiency Syndrome/AIDS and hepatitis B. At present, now the SARS-CoV-2 pandemic has been added to the list, as a result of which needle-free injections have gained even more traction in the healthcare industry. The entire process of needle free injection takes only 0.5 seconds or less, and the time saved is extremely crucial when it comes to finding the novel coronavirus vaccine.

Despite the lockdown across countries, technological innovations in relation to pain-free drug self-administration and transportation have been quite frequent, benefitting the global market. Various firms and researchers are constantly on the lookout for painless techniques that facilitate needle free drug delivery. To illustrate, in August 2020, a researchers’ team from Singapore (NTU Singapore), Agency for Science, Technology and Research and Nanyang Technological University has created a technique to deliver drugs that involves application of temporal pressure. This development can result in painless transdermal drug delivery such as insulin.

Top Industry Contenders

Top industry contenders outlined in the MRFR research include Needle-Free Injection Market players D'Antonio Consultants International, Inc., PenJet Corporation, Medical International Technology, Inc., CROSSJECT, PharmaJet, Inc., MIKA MEDICAL CO., National Medical Products Inc., Endo Pharmaceuticals Inc., Antares Pharma Inc., Inovio Pharmaceuticals Inc., Valeritas Holdings, Inc., INJEX Pharma GmBH, European Pharma Group, to name a few.

Segmental Review

Product type, technology, usability, medical type, site of delivery, application and end-users are listed as the main segments according to which the needle free injection industry has been considered in the study.

The primary product types covered are prefilled as well as fillable needle free injection research. By 2023, the fillable segment can be in the lead as the syringes are extensively used by the practitioners, in which the vaccine is filled on the basis of the disease.

Spring-based, jet-based and laser-powered are the key technologies analyzed in the MRFR report. Between these, it is anticipated that the jet-based category can expand to USD 10,391.3 million by the year 2023, as it is the fastest technique of delivery compared to others. Its rising preference in hospitals as made it the largest segment in the global market.

Usability-wise, the top categories can be reusable and disposable needle free injectors. Reusable needle free injections can observe the highest growth rate of 15.90% in the ensuing period.

In terms of the medication type, the market can be considered for powder-based, liquid-based and projectile/depot-based needle free injections. In 2017, liquid-based needle free injections were identified as the top segment in the market and it can continue being in the lead segment throughout the evaluation period, given its simplified working mechanism.

Given the delivery site, intramuscular, subcutaneous and intradermal are the key sections considered in the report. Intramuscular delivery site can be the highest revenue generating segment in the needle free injection industry, as these muscles are able to absorb the vaccine at a higher pace than other parts.

Oncology, insulin delivery, vaccination, and more are some of the key market applications. The insulin delivery application can procure the fastest expansion rate of 14.9%, driven by the massive population of diabetics that demand pain-free solutions to receive insulin.

Hospitals and clinics, homecare settings, ambulatory surgical centers, and more are the key end-users in the industry. The lead is anticipated to be taken by the hospitals and clinics category by 2023, because of the escalating demand for advanced devices that can efficiently deliver the vaccine for chronic illnesses.

Regional Study

The regional study of the global market comprises the Middle East and Africa (MEA), Asia Pacific (APAC), Europe, and the Americas.

The biggest gainer can be the Americas as the cases of chronic diseases have risen considerably over the years. The mounting preference for self-administrative devices and the frequent technology-based breakthroughs in biotechnology and pharmaceutical industries also contribute to the market expansion here. The rising investments by top contenders and the high awareness level among people are also projected to enhance the market size in the region.

Europe can be a formidable contender in the global market, backed by the vast pool of world renowned players present in the region along with the extensive healthcare infrastructure. The needle free injection market in Europe is advancing as a result of the rapidly increasing patient pool and the R&D spending by the government as well as pharmaceutical firms for chronic pain management and diabetes.

A robust growth rate can be procured by the APAC market, as a result of the fast developing countries like India and China and the boosted healthcare spending in these nations. The presence of the massive patient population and the growing need to adhere to the strict quality and safety standards by leading manufacturers can mean significant product sale in the following years. On the other hand, MEA has managed to seize the smallest share in the global market, owing to the rigid government standards and policies coupled with the low focus on healthcare development.